Few would place Recursion Pharmaceuticals (NASDAQ: RXRX), a little-known biotech company, in the same league as these tech ...
Small-cap biotech companies can deliver outsized returns over the long run if they develop breakthrough medicines that go on to generate massive sales. However, some of these smaller drugmakers aren't ...
Recursion Pharmaceuticals uses AI to expedite the laborious process of developing drugs. The company could benefit from industry-wide regulatory changes as well as its own clinical progress. However, ...
In recent developments, Recursion Pharmaceuticals unveiled advances in its AI platform for drug discovery, forming collaborations with major pharmaceutical groups including Sanofi, Roche/Genentech, ...
Schrödinger (NASDAQ: SDGR) and Recursion Pharmaceuticals (NASDAQ: RXRX) are both biotechs that want to use AI to streamline the drug discovery and development process. And that makes them hot stocks ...
Recursion Pharmaceuticals (RXRX) has grabbed attention following the announcement of its merger with Exscientia, as well as updates on late-stage trial milestones and new regulatory clearances for ...
Hosted on MSN
Does Recursion Pharmaceuticals (RXRX) Have the Potential to Rally 27.96% as Wall Street Analysts Expect?
Shares of Recursion Pharmaceuticals (RXRX) have gained 4% over the past four weeks to close the last trading session at $7.26, but there could still be a solid upside left in the stock if short-term ...
Recursion Pharmaceuticals has an exciting approach to developing therapies. The company recently reported positive phase 2 results for one of its products. While this small biotech looks promising, it ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback